Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. (Q39837221)

15 September 2017

1 reference

title

Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. (English)

1 reference

15 September 2017

1 reference

ChEBI release 2020-05-28

1 reference

R N Brogden

1 reference

15 September 2017

B Holmes

1 reference

15 September 2017

D M Richards

series ordinal

1 reference

15 September 2017

publication date

1 December 1985

1 reference

15 September 2017

1 reference

15 September 2017

1 reference

15 September 2017

1 reference

15 September 2017

page(s)

482-513

1 reference

In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents

15 September 2017

cites work

1 reference

12 December 2020

The antimicrobial spectrum of norfloxacin

1 reference

12 December 2020

Activity of the newer quinolones against Chlamydia trachomatis

1 reference

12 December 2020

Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations

1 reference

12 December 2020

Investigations into the mechanism of action of the antibacterial agent norfloxacin

1 reference

12 December 2020

Norfloxacin penetration into human renal and prostatic tissues

1 reference

12 December 2020

Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes.

1 reference

12 December 2020

In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent

1 reference

12 December 2020

Treatment of Penicillin-ResistantNeisseria gonorrhoeaewith Oral Norfloxacin

1 reference

12 December 2020

Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function--some preliminary results

1 reference

12 December 2020

Comparative trial of norfloxacin and trimethoprim-sulfamethoxazole in the treatment of women with localized, acute, symptomatic urinary tract infections and antimicrobial effect on periurethral and fecal microflora

1 reference

12 December 2020

In vitro activity of CI-919 (AT-2266), an oral antipseudomonal compound

1 reference

12 December 2020

Norfloxacin versus cotrimoxazole in the treatment of lower urinary tract infections

1 reference

12 December 2020

In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents

1 reference

12 December 2020

Nalidixic acid resistance: A second genetic character involved in DNA gyrase activity

1 reference

12 December 2020

Norfloxacin disposition after sequentially increasing oral doses

1 reference

12 December 2020

In vitro activities of the spectinomycin analog U-63366 and four quinolone derivatives against Neisseria gonorrhoeae

1 reference

12 December 2020

Comparative study using norfloxacin and amoxycillin in the treatment of complicated urinary tract infections in geriatric patients

1 reference

12 December 2020

Incomplete cross-resistance of nalidixic and pipemidic acid-resistant variants of Serratia marcescens against ciprofloxacin, enoxacin, and norfloxacin

1 reference

12 December 2020

Bactericidal activities of chloramphenicol and eleven other antibiotics against Salmonella spp

1 reference

12 December 2020

Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid

1 reference

12 December 2020

Clinical evaluation of norfloxacin versus cotrimoxazole in urinary tract infections

1 reference

12 December 2020

Norfloxacin (MK-0366, AM-715): In vitro activity and cross-resistance with other organic acids including quality control limits for disk diffusion testing

1 reference

12 December 2020

In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid

1 reference

12 December 2020

Comparative in vitro activity of norfloxacin (MK-0366) and ten other oral antimicrobial agents against urinary bacterial isolates

1 reference

12 December 2020

The comparative activity of norfloxacin with other antimicrobial agents against Gram-positive and Gram-negative bacteria.

1 reference

12 December 2020

Antibacterial activity of norfloxacin

1 reference

12 December 2020

Comparative in vitro activities of norfloxacin (MK-0366) and six commonly used antimicrobial agents against 199 urinary isolates showing various degrees of antibiotic resistance

1 reference

12 December 2020

In-vitro studies with ciprofloxacin, a new 4-quinolone compound.

1 reference

12 December 2020

Multiclinic comparative study of norfloxacin and trimethoprim-sulfamethoxazole for treatment of urinary tract infections

1 reference

12 December 2020

Mechanism of renal excretion of AM-715, a new quinolonecarboxylic acid derivative, in rabbits, dogs, and humans

1 reference

12 December 2020

Norfioxacin (MK–0366) treatment of urinary tract infections in hospitalized patients

1 reference

12 December 2020

Norfloxacin: activity against urinary tract pathogens and factors influencing the emergence of resistance

1 reference

12 December 2020

Comparative in vitro activities of ten antimicrobial agents against bacterial enteropathogens

1 reference

12 December 2020

In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim

1 reference

12 December 2020

Norfloxacin--a new antibacterial agent with anti-pseudomonal activity

1 reference

12 December 2020

Norfloxacin, amoxycillin, cotrimoxazole and nalidixic acid: A summary of 3-day and 7-day therapy studies in the treatment of urinary tract infections

1 reference

12 December 2020

Norfloxacin-induced rheumatic disease.

1 reference

12 December 2020

Comparison of the in vitro activity of ciprofloxacin (Bay o 9867) and norfloxacin against gastrointestinal tract pathogens

1 reference

12 December 2020

Comparative evaluation of recently developed quinolone compounds--with a note on the frequency of resistant mutants.

1 reference

12 December 2020

In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim

1 reference

12 December 2020

Norfloxacin for the treatment of uncomplicated urinary tract infections

1 reference

12 December 2020

In-vitro activity of pefloxacin compared to enoxacin, norfloxacin, gentamicin and new beta-lactams

1 reference

12 December 2020

A review of urinary tract infection in the elderly

1 reference

12 December 2020

Study on the antibacterial activity of penicillins and cephalosporines in urine (author's transl)

1 reference

12 December 2020

Comparative in vitro activities of selected antimicrobial agents against Aeromonas species and Plesiomonas shigelloides

1 reference

12 December 2020

In vitro antibacterial activity of norfloxacin (MK-0366, AM-715) and other agents against gastrointestinal tract pathogens

1 reference

12 December 2020

In vitro activity of norfloxacin in urine compared to that of cinnoxacin, nalidixic acid and pipemidic acid

1 reference

12 December 2020

Treatment of simple urinary tract infections in general practice with a 3-day course of norfloxacin

1 reference

12 December 2020

Comparative in vitro activity of Sch 29,482, a new oral penem, against Neisseria gonorrhoeae

1 reference

12 December 2020

Frequency of appearance of resistant variants to norfloxacin and nalidixic acid

1 reference

12 December 2020

Comparison of antimicrobial susceptibility patterns of Campylobacter jejuni and Campylobacter coli

1 reference

12 December 2020

Bactericidal intraprostatic concentrations of norfloxacin

1 reference

12 December 2020

The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid.

1 reference

12 December 2020

Norfloxacin: in vitro activity compared with that of seven other antibacterial agents against urinary tract pathogens

1 reference

12 December 2020

Efficacy of norfloxacin in urinary tract infection biological effects on vaginal and fecal flora.

1 reference

12 December 2020

Treatment of acute urinary infection by norfloxacin or nalidixic acid/citrate: a multi-centre comparative study

1 reference

12 December 2020

Recovery of norfloxacin in feces after administration of a single oral dose to human volunteers

1 reference

12 December 2020

Susceptibility of Clostridium difficile strains to new antibiotics: quinolones, efrotomycin, teicoplanin and imipenem

1 reference

12 December 2020

Norfloxacin: a three-day course for the treatment of urinary tract infection

1 reference

12 December 2020

Comparison of the antibacterial activity of norfloxacin (MK 0366, AM 715), a new organic acid, with that of other orally absorbed chemotherapeutic agents

1 reference

12 December 2020

In vitro comparison of norfloxacin with nalidixic acid, cinoxacin and oxolinic acid

1 reference

12 December 2020

Comparative activities of norfloxacin and fifteen other antipseudomonal agents against gentamicin-susceptible and -resistant Pseudomonas aeruginosa strains

1 reference

12 December 2020

Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid

1 reference

12 December 2020

Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR 810 (a new cephalosporin), RU28965 (a new macrolide), and other agents against enteropathogens

1 reference

12 December 2020

The activity of enoxacin against clinical bacterial isolates in comparison with that of five other agents, and factors affecting that activity

1 reference

12 December 2020

Pharmacokinetics of norfloxacin in renal failure

1 reference

12 December 2020

Norfloxacin versus trimethoprim-sulfamethoxazole in the therapy of uncomplicated, community-acquired urinary tract infections

1 reference

12 December 2020

In vitro activities of ciprofloxacin, norfloxacin, pipemidic acid, cinoxacin, and nalidixic acid against Chlamydia trachomatis

1 reference

12 December 2020

Norfloxacin and the antibacterial gamma pyridone beta carboxylic acids

1 reference

12 December 2020

The pharmacokinetics and tissue penetration of enoxacin and norfloxacin

1 reference

12 December 2020

The pharmacokinetics and tissue penetration of norfloxacin

1 reference

12 December 2020

Review of bacterial resistance--a challenge to the treatment of urinary infection

1 reference

12 December 2020

A review of the problem of urinary infection management and the evaluation of a potential new antibiotic

1 reference

12 December 2020

N-formimidoyl-thienamycin and norfloxacin against multiple-resistant Pseudomonas aeruginosa strains. Combined in vitro activity and comparison with 14 other antibiotics

1 reference

12 December 2020

In vitro and in vivo activity of DL-8280, a new oxazine derivative

1 reference

12 December 2020

Norfloxacin--a review of pharmacology and tissue penetration

1 reference

12 December 2020

Bactericidal effects of norfloxacin towards bacteria in urine

1 reference

12 December 2020

In vitro antibacterial activity of norfloxacin (MK-0366).

1 reference

12 December 2020

In vitro activity of ciprofloxacin (Bay o 9867)

1 reference

12 December 2020

Rapid selection of organisms with increasing resistance on subinhibitory concentrations of norfloxacin in agar

1 reference

12 December 2020

Norfloxacin in prostatitis: correlation between HPLC tissue concentrations and clinical results

1 reference

12 December 2020

Norfloxacin versus cotrimoxazole in the treatment of uncomplicated urinary tract infections--a multi-centre trial

1 reference

12 December 2020

The treatment of Pseudomonas aeruginosa urinary tract infections with norfloxacin

1 reference

12 December 2020

In vitro activity of norfloxacin against Neisseria gonorrhoeae

1 reference

12 December 2020

Comparative in-vitro activity of norfioxacin and selected antimicrobial agents against urinary tract pathogens and Neisseria gonorrhoeae

1 reference

12 December 2020

In vitro antibacterial properties of AT-2266, a new pyridonecarboxylic acid

1 reference

12 December 2020

In-vitro activity of enoxacin, ofloxacin, norfloxacin and nalidixic acid

1 reference

12 December 2020

Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage

1 reference

12 December 2020

In vitro antibacterial activity of AM-715, a new nalidixic acid analog

1 reference

12 December 2020

10.2165/00003495-198530060-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

15 September 2017

1020345008

0 references

1 reference